As a result of this finding and efficient analysis of Siglec‐1 on CD14+ cells, we started to routinely measure Siglec‐1 in all patients with COVID‐19 admitted to ICUs to distinguish between patients with high and low IFN signature to test the hypothesis of an association of IFN signature and outcome of the patients. The gene discussed is IFNA1; the disease is COVID-19.